Tuesday, October 6, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· July 13, 2026

Brown-Forman Announces President & CEO Lawson Whiting to Retire

View original at finance.yahoo.com

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Stated the Board appreciates Whiting giving ample notice, enabling a robust internal and external talent review; expressed confidence in the business and long-term stakeholder value creation, and noted Whiting will continue advancing strategic priorities including geographic expansion, brand building, and operational efficiency during the succession process.

    60% confidence
  • Thanked Lawson Whiting for nearly 30 years of dedication to Brown-Forman, describing him as a steadfast steward of the founder's vision who built the most premium portfolio in the industry; noted Jack Daniel's international expansion, Woodford Reserve's rise to leading super-premium American whiskey, and Old Forester tripling in volume and increasing net sales six-fold over the last decade.

    60% confidence
  • Described leading Brown-Forman as the privilege of a lifetime, credited his tenure to the people he worked with, said the company enters this transition from a position of strength with principled leadership, iconic brands, and deep talent, and expressed confidence the succession process will find the right next leader.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com